{"title":"Lymphocyte Subsets Changes in Children with Acute Lymphoblastic Leukemia during Chemotherapy.","authors":"Arijeta Hasani, Aleksandar Petlickovski, Irina Panovska, Teodora Brnjarcevska, Nevenka Ridova, Svetlana Kocheva","doi":"10.2478/prilozi-2025-0013","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with chemotherapy significantly impacting immune cell populations. This study evaluates changes in lymphocyte subsets in children with ALL during treatment. <b>Methods</b>: A retrospective-prospective study analyzed 17 pediatric patients (aged 2-12 years) treated at the University Clinic for Children's Disease- Skopje following the BFM ALL-IC 2002 protocol. Lymphocyte subsets (CD3, CD4, CD19, CD45) were assessed before chemotherapy, after induction, and after reinduction using flow cytometry. <b>Results</b>: Children with ALL exhibited reduced cellular immunity at the end of therapy. Lymphocyte depletion was observed in all patients following the induction phase. A statistically significant difference in CD19+ cell values across the three time points was confirmed (p=0.017). Post-hoc analysis revealed significantly lower CD19+ cell values after induction compared to baseline (1.22 vs. 15.3, p=0.008) and significantly lower values at the end of therapy compared to pre-therapy levels (2.5 vs. 15.3, p=0.021). <b>Conclusion</b>: Intensive chemotherapy induces profound immunosuppression in pediatric ALL patients, primarily affecting B cells. These findings highlight the necessity for immune function assessment and consideration of supportive immunotherapy.</p>","PeriodicalId":74492,"journal":{"name":"Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)","volume":"46 2","pages":"49-56"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/prilozi-2025-0013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with chemotherapy significantly impacting immune cell populations. This study evaluates changes in lymphocyte subsets in children with ALL during treatment. Methods: A retrospective-prospective study analyzed 17 pediatric patients (aged 2-12 years) treated at the University Clinic for Children's Disease- Skopje following the BFM ALL-IC 2002 protocol. Lymphocyte subsets (CD3, CD4, CD19, CD45) were assessed before chemotherapy, after induction, and after reinduction using flow cytometry. Results: Children with ALL exhibited reduced cellular immunity at the end of therapy. Lymphocyte depletion was observed in all patients following the induction phase. A statistically significant difference in CD19+ cell values across the three time points was confirmed (p=0.017). Post-hoc analysis revealed significantly lower CD19+ cell values after induction compared to baseline (1.22 vs. 15.3, p=0.008) and significantly lower values at the end of therapy compared to pre-therapy levels (2.5 vs. 15.3, p=0.021). Conclusion: Intensive chemotherapy induces profound immunosuppression in pediatric ALL patients, primarily affecting B cells. These findings highlight the necessity for immune function assessment and consideration of supportive immunotherapy.
背景:急性淋巴细胞白血病(ALL)是最常见的儿童恶性肿瘤,化疗显著影响免疫细胞群。本研究评估了ALL患儿在治疗期间淋巴细胞亚群的变化。方法:一项回顾性-前瞻性研究分析了在斯科普里大学儿童疾病诊所接受BFM ALL-IC 2002方案治疗的17例儿童患者(2-12岁)。淋巴细胞亚群(CD3、CD4、CD19、CD45)在化疗前、诱导后和再诱导后使用流式细胞术进行评估。结果:ALL患儿在治疗结束时表现出细胞免疫功能降低。诱导期后,所有患者均出现淋巴细胞耗竭。三个时间点的CD19+细胞值有统计学意义差异(p=0.017)。事后分析显示,诱导后的CD19+细胞值与基线相比显著降低(1.22 vs. 15.3, p=0.008),治疗结束时的CD19+细胞值与治疗前水平相比显著降低(2.5 vs. 15.3, p=0.021)。结论:强化化疗在儿童ALL患者中引起严重的免疫抑制,主要影响B细胞。这些发现强调了免疫功能评估和考虑支持免疫治疗的必要性。